Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects.

The company’s lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). In addition to its IPF program, Aerovate is advancing preclinical molecules designed to target other chronic lung conditions, including scleroderma-related interstitial lung disease and chronic obstructive pulmonary disease. Each program is engineered to exploit the company’s aerosol technology, which is designed to enhance pulmonary deposition and improve patient tolerability compared with oral therapies.

Founded in 2020 and headquartered in the United States, Aerovate Therapeutics has assembled a team of experienced drug developers and clinicians to shepherd its pipeline through clinical development. The company collaborates with leading research institutions and regulatory authorities to support trial design and anticipate broader geographic expansion, positioning Aerovate to address significant unmet needs in fibrotic and inflammatory lung diseases worldwide.

Key Stats

• Today's Range: $7.00 to $7.85
• 50-Day Range: $6.77 to $9.82
• 52-Week Range: $56.35 to $105.00
• Volume: 65,127 shs
• Average Volume: 12,438 shs
• Market Capitalization: $223.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVTE Stock Analysis - Frequently Asked Questions

How have AVTE shares performed this year?

Aerovate Therapeutics' stock was trading at $92.75 at the beginning of 2025. Since then, AVTE shares have decreased by 91.7% and is now trading at $7.71.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced its earnings results on Friday, April, 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.50) by $7.35.

When did Aerovate Therapeutics' stock split?

Shares of Aerovate Therapeutics reverse split before market open on Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aerovate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 4/25/2025
• Today: 9/19/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTE
• CIK: 1798749
• Web: aerovatetx.com
• Phone: 617-443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.19%
• Return on Assets: -77.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.78
• Quick Ratio: 8.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.96 per share
• Price / Book: 1.95

Miscellaneous

• Outstanding Shares: 28,985,000
• Free Float: 21,685,000
• Market Cap: $223.47 million
• Optionable: Optionable
• Beta: 0.95